Technical Comment on EU Regulatory Developments Affecting Tea Tree Oil by ATTIA

1 month ago

Current EU regulatory discussions on tea tree oil have caused concern, but ATTIA emphasises that this reflects a procedural inconsistency—not a new safety issue. While the proposed CLP classification relies on a hazard-only assessment, the SCCS’s 2023 risk-based review concluded tea tree oil is safe for cosmetic use within established limits..

Read the full article

Enjoy unrestricted access to expert insights, formulation guides, and green cosmetic trends — free with registration.

Already have an account? Login here

ATTIA Ltd represents more than 90% of the Australian tea tree oil industry. As the

peak body for producers, exporters and associated industries, we welcome the

opportunity to clarify the current EU regulatory developments and their relevance to

formulators worldwide.

The proposed harmonised classification for tea tree oil currently progressing

through the EU system has generated understandable concern across cosmetics,

personal care, biocides and other downstream sectors. For Australian producers,

formulators and global brands, the issue is not a new safety signal but the

implications of a regulatory pathway that does not reflect the totality of evidence.

1.Divergence in EU Scientific Assessments

The current proposal originates from the Risk Assessment Committee (RAC) under

the CLP Regulation, which applies a hazard-only methodology. This approach does

not consider exposure, realistic use conditions, or the extensive real-world history of

tea tree oil in formulated products.

This stands in clear contrast to the SCCS’s comprehensive 2023 opinion, which

reviewed the full toxicological dataset, dermal exposure scenarios, impurity profiles

and consumer use patterns. The SCCS concluded that tea tree oil can be used

safely in cosmetic applications within established conditions.

The inconsistency between these two assessments — one hazard-based, one risk-

based — has created significant uncertainty for global markets. From ATTIA’s

perspective, this is fundamentally a process issue, not a question of product safety.

Regulatory decisions with wide-ranging commercial and scientific ramifications

must be grounded in the full body of evidence.

2.ISO 4730: Identity Standard, Not a Quality or Safety Standard

Many formulators have asked whether the EU developments relate specifically to

compliance with ISO 4730. They do not.

ISO 4730 defines the characteristic identity profile of Melaleuca alternifolia essential

oil, specifying compositional ranges and basic physical properties. It

does not assess:

• purity

• adulteration

• traceability

• safety

• agricultural or manufacturing practice

Because it is an identity-only standard, it is technically possible for adulterated or

reconstructed products to meet the ISO profile if blended to fall within the required

terpene ranges.

For Australian producers, ISO 4730 is therefore the starting point, not the quality

benchmark.

3.ATTIA’s Code of Practice: The Global Quality and Purity Standard

The ATTIA Code of Practice (COP), now in its 25th year, goes far beyond ISO 4730

to establish a comprehensive quality, purity and authenticity framework. It includes:

• impurity and adulteration testing

• strict good agricultural and distillation practice

• independent auditing

• full traceability from plantation to finished oil

• verification of batch authenticity

Formulators seeking confidence in ingredient integrity should view ATTIA COP–

certified oil as the benchmark for high-quality, fully traceable Australian supply.

4.Guidance for Formulators and Brands

While the EU process continues, formulators are encouraged to:

• Use pure Australian tea tree oil within recognised safe-use levels and

according to regional requirements.

• Request full documentation from suppliers, including Certificate of Analysis

and evidence of COP compliance.

• Avoid premature reformulation driven by misconceptions rather than

regulatory facts.

• Seek clarification early when preparing EU or global cosmetic dossiers.

5.ATTIA’s Ongoing Commitment

ATTIA remains actively engaged with stakeholders and committed to providing

transparent, evidence-based information throughout the EU process. Formulators,

R&D teams and procurement specialists seeking further guidance are welcome to

contact ATTIA directly.

Share this post...

Facebook
Twitter
LinkedIn
WhatsApp
Email